Perceptions Related to Pharmacological Treatment of Opioid Dependence Among Individuals Seeking Treatment at a Tertiary Care Center in Northern India: A Descriptive Study.
Perceptions of individuals with opioid dependence regarding medications used for long-term management of the condition have been explored only by a handful of studies. Interestingly, no study had compared the perceptions regarding buprenorphine, buprenorphine-naloxone, and oral naltrexone in the opioid-dependent subjects from the same setting.



The present study aimed to examine the perceptions related to treatment of opioid dependence with buprenorphine, buprenorphine-naloxone, and oral naltrexone among individuals seeking help at a tertiary care center.



This was a cross-sectional, observational study with consecutive sampling. Sociodemographic data, Drug Abuse Monitoring System questionnaire, perceptions questionnaire, clinical interview to elicit drug use history, treatment history and details of prior abstinence attempts were completed.



Eighty-five subjects were recruited in the study. Fear of becoming dependent (35.3%) was the most common harm reported while withdrawal control (82.4%) was the most common benefit reported with buprenorphine preparations. Precipitated withdrawals (21.2%) were the most common harm reported and prevention of relapse (53%) was the most common benefit reported with oral naltrexone. While patients who believed that buprenorphine or naltrexone were harmful reported durations of treatment that were much shorter than those who did not so believe, there was no statistically significant difference in the actual duration and period of abstinence (p = .34; p = .62). Sociodemographic profile, perceptions related to dosing, nature of medication, expectations from treatment, and duration of illness were also described.
a Department of Psychiatry , All India Institute of Medical Sciences , New Delhi , India.
Sathya
S
Prakash
b National Drug Dependence Treatment Centre , All India Institute of Medical Sciences , New Delhi , India.
Yatan
Y
Balhara
D002047:Buprenorphine; D003430:Cross-Sectional Studies; D006801:Humans; D007194:India; D009292:Narcotic Antagonists; D009293:Opioid-Related Disorders; D062606:Tertiary Care Centers
D009292:Narcotic Antagonists; D002047:Buprenorphine
Perceptions; buprenorphine; buprenorphine-naloxone; naltrexone; opioid substitution therapy